Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. "TRIFOUR Study"

NCT05181462 is registered in ClinicalTrials.gov with Cantargia AB as lead sponsor.

NCT NCT05181462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05181462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. "TRIFOUR Study"
Lead sponsor
Cantargia AB
Phase
Phase 1/2
Overall status
Completed
Start date
January 11, 2022
Completion date
May 8, 2026
Enrollment
117 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer